Company Profile:

AbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. The company was incorporated in 2012 and is based in North Chicago, Illinois.

Recent News:

The company will announce its fourth-quarter and full-year 2018 financial results on Friday, January 25, 2019 before the market opens. It will host a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern).

On Jan. 03, 2019, AbbVie and Tizona Therapeutics, Inc. announced that they have entered into a global, strategic collaboration to develop and commercialize CD39-targeted therapeutics, including TTX-030, a first-in-class antibody for the treatment of cancer.

Fundamental Analysis:

Ninestocks analyzes several different financial aspects: Growth, Profitability, solvency and efficiency.

Growth – Measures the growth of both the company’s income statement and cash flow.

@@@@@

Profitability – Measures the historical price movement of the stock.

@@@@@

Solvency – Measures the solvency of the company based on several ratios.

@@@@@

Efficiency – Measures the strength and historic growth of a company’s return on invested capital.

@@@@@

Conclusion:

ABBV’s strengths can be seen in its strong growth, strong profitability and better effficiency compared with its peers. Its revenue has increased over recent several years. Technical indicators signal the bullish signs, as there is a bullish crossover in Stochastic oscillator, the MACD is trying to cross back up and the RSI stands at 54.96 with positive bias. We rate AbbVie Inc. (ABBV) a STRONG BUY.